Bootcamp Day: A Durability Deep Dive
Monday, 30th January
9:00 am Bootcamp Registration & Coffee
9:55 am Chair’s Opening Remarks
Enhancing Cell Potency Without Increasing Toxicity to Decrease Cell Exhaustion
10:00 am Utilising Cell Therapies in Combination with Therapy Enhancers to Increase Potency
Synopsis
- Assessing rational drug combinations to evaluate the most suitable partner to pair with different cell therapies
- Proving your chosen combination is advantageous and effective to ensure increased potency in vivo
- Comparing cell therapy combinations with cell engineering to review where each method is best-suited
10:30 am CAR-T Cells Generated by Non-Viral Gene Editing – From Autologous to Allogeneic Approaches
Synopsis
- Gene editing tools to disrupt and replace the endogenous T cell receptor to avoid allo-reactivity
- Additional genetic modifications to enhance the persistence of allogeneic T cells including base editing
- Non-viral gene editing strategies for sustainable and cost-efficient CAR T development
11:00 am Morning Durabili-Tea and Coffee
11:45 am VIRTUAL Development of Highly Potent Allogeneic NK Cell Therapies Using NAM Technology and Engineering
Synopsis
- Engineering proliferal blood NKs to target liquid and solid tumours
- Utilising cell culture with NAM technology to create potent NK cells without manipulation
12:15 pm Co-Stimulatory CAR-T Approach in γδ T Cells: Avoiding the On-Target Off-Tumour Toxicity
Synopsis
- The co-stimulatory approach for CAR-equipped γ9δ2 T cells
- Enhancing tumour cell kill
- Minimising toxicity against normal cells
12:45 pm Lunch Refreshments & Networking
Reinventing Therapy Persistence to Mediate Long-Term Disease Tackling
1:45 pm Multiplex Engineering Using the miCAR Platform Yields Persistent, Highly Active and Cost-Effective Cell Therapies
Synopsis
- Moving beyond editing to engineer immune cells
- Engineering cells which are less prone to exhaustion whilst maintaining efficacy
- Simplified, cost effective manufacturing improves CoGs
2:15 pm Round Table: Understanding the Best Method to Increase Durability Selecting Advantageous Cell Subpopulations to Mediate Durable Targeting
Synopsis
- Selecting advantageous cell subpopulations to mediate durable targeting
- Assessing the factors affecting therapy persistence to identify where intervention is required
- Evaluating the ideal length of therapy duration to create a goal of therapy persistence mechanisms
- Reviewing location of therapeutics cells in vivo to distinguish area of targeting
3:00 pm VIRTUAL Off-the-Shelf Allogeneic EBV T Cells: Ushering in the Next Wave of Innovation
Synopsis
- Discuss the journey that led to the historic EU approval of the first-ever allogeneic T-cell therapy globally
- Highlight the qualities that make allogeneic Epstein-Barr virus (EBV) T cells a highly versatile platform for targeting EBV-driven disease
- Explore how this platform can be modified with a chimeric antigen receptor (CAR) to target a wide range of non-EBV-associated disease